Zymeworks Inc. $ZYME Stock Holdings Reduced by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA reduced its position in Zymeworks Inc. (NASDAQ:ZYME – Free Report) by 38.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 188,468 shares of the company’s stock after selling 119,719 shares during the quarter. Pictet Asset Management Holding SA’s holdings in Zymeworks were worth $5,121,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of ZYME. Calamos Advisors LLC purchased a new stake in Zymeworks during the third quarter worth about $1,232,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Zymeworks in the third quarter valued at approximately $96,000. ProShare Advisors LLC boosted its stake in shares of Zymeworks by 91.5% in the third quarter. ProShare Advisors LLC now owns 16,390 shares of the company’s stock valued at $434,000 after purchasing an additional 7,833 shares during the period. State of Wyoming boosted its stake in shares of Zymeworks by 405.9% in the third quarter. State of Wyoming now owns 14,125 shares of the company’s stock valued at $374,000 after purchasing an additional 11,333 shares during the period. Finally, China Universal Asset Management Co. Ltd. grew its holdings in shares of Zymeworks by 11.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 12,947 shares of the company’s stock valued at $352,000 after purchasing an additional 1,325 shares in the last quarter. 92.89% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Zymeworks

In other Zymeworks news, EVP Adam Schayowitz sold 13,832 shares of the stock in a transaction that occurred on Friday, October 9th. The shares were sold at an average price of $25.85, for a total value of $357,557.20. Following the sale, the executive vice president directly owned 23,205 shares of the company’s stock, valued at approximately $599,849.25. This represents a 37.35% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 37.73% of the company’s stock.

Zymeworks Price Performance

Shares of ZYME stock traded down $0.23 during trading hours on Friday, reaching $26.24. 774,980 shares of the stock were exchanged, compared to its average volume of 1,376,009. The business’s fifty day moving average is $27.32 and its two-hundred day moving average is $25.48. Zymeworks Inc. has a 12-month low of $18.20 and a 12-month high of $31.97. The firm has a market capitalization of $1.81 billion, a P/E ratio of 50.46 and a beta of 1.32.

Zymeworks (NASDAQ:ZYME – Get Free Report) last issued its earnings results on Monday, November 9th. The company reported $2.28 earnings per share for the quarter, beating the consensus estimate of $2.27 by $0.01. Zymeworks had a net margin of 16.10% and a return on equity of 22.23%. The firm had revenue of $512.92 million for the quarter, compared to analysts’ expectations of $227.40 million. During the same quarter last year, the company earned ($0.26) earnings per share. The firm’s revenue was up 828.7% compared to the same quarter last year. As a group, equities research analysts predict that Zymeworks Inc. will post 1.31 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. HC Wainwright increased their target price on shares of Zymeworks from $55.00 to $56.00 and gave the stock a “buy” rating in a report on Tuesday, November 10th. B. Riley Financial restated a “buy” rating and issued a $44.00 price target (up from $40.00) on shares of Zymeworks in a research note on Monday, August 10th. Citizens Jmp upped their price objective on Zymeworks from $32.00 to $39.00 and gave the stock a “market outperform” rating in a research report on Friday. Citigroup increased their price objective on Zymeworks from $39.00 to $44.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, Wolfe Research assumed coverage on Zymeworks in a research note on Thursday, September 17th. They issued an “outperform” rating on the stock. Twelve analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $43.25.

Read Our Latest Analysis on ZYME

Latest Zymeworks News

Investors following ZYME have been watching these news items:

  • Positive Sentiment: Citizens JMP raised its price target to $39 from $32 and assigned a “market outperform” rating, implying substantial upside from the referenced $26.24 share price. TickerReport article
  • Positive Sentiment: A report linked Zymeworks’ improved outlook to a milestone payment and a profitable quarter. The company’s latest reported results also beat the cited EPS consensus slightly, while revenue was well above estimates—supportive news, though milestone revenue may not recur. Milestone Payment Lifts Zymeworks Stock Outlook After Profitable Quarter
  • Negative Sentiment: HC Wainwright cut its estimates across several upcoming quarters, lowering its FY2026 EPS forecast to $1.19 from $1.51 and moving its FY2027 outlook from $1.32 profit to a projected $0.39 loss. The analyst retained a Buy rating and $56 target, but the revisions signal a less favorable earnings outlook beyond the recent quarter.

Zymeworks Profile

(Free Report)

Zymeworks Inc. is a biotechnology company headquartered in Vancouver, Canada, that develops engineered medicines, with a focus on treatments for cancer and other serious diseases. Its antibody-engineering technologies are designed to create therapies that can engage multiple biological targets or modify immune responses. The company’s lead program is zanidatamab, a HER2-targeted bispecific antibody. In the United States, it is marketed by partner Jazz Pharmaceuticals as Ziihera for certain adults with previously treated, unresectable or metastatic biliary tract cancer.

Featured Articles

Want to see what other hedge funds are holding ZYME? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zymeworks Inc. (NASDAQ:ZYME – Free Report).

Institutional Ownership by Quarter for Zymeworks (NASDAQ:ZYME)

Receive News & Ratings for Zymeworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymeworks and related companies with MarketBeat.com's FREE daily email newsletter.